Products for Research Use Only
RegisterLogin

Kanglexin

CAT: 0804-HY-164853-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-164853-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis[1][2][3][4].
CAS Number
2228847-12-7
UNSPSC
12352005
Target
AMPK; ERK; FGFR; NOD-like Receptor (NLR) ; Pyroptosis
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; Immunology/Inflammation; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/kanglexin.html
Concentration
10mM
Purity
99.65
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C1C2=C(C(C3=C(C=C(C)C=C13)O)=O)C(O)=CC(OC(CCC(OCC)=O)=O)=C2
Molecular Formula
C21H18O8
Molecular Weight
398.36
References & Citations
[1]Bian Y, et al. Kanglexin, a novel anthraquinone compound, protects against myocardial ischemic injury in mice by suppressing NLRP3 and pyroptosis. Acta Pharmacol Sin. 2020 Mar;41 (3) :319-326.|[2]Li X, et al. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway. Biomed Pharmacother. 2021 Jan;133:110802. |[3]Yang S, et al. Kanglexin counters vascular smooth muscle cell dedifferentiation and associated arteriosclerosis through inhibiting PDGFR. Phytomedicine. 2024 Jul 25;130:155704. |[4]Zhao Y, et al. Kanglexin accelerates diabetic wound healing by promoting angiogenesis via FGFR1/ERK signaling. Biomed Pharmacother. 2020 Dec;132:110933.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
NLRP3

Alternative Products

CatalogName
T203479-01Kanglexin

Popular Products